Great West Life Assurance Co. Can decreased its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 11.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 415,675 shares of the company’s stock after selling 55,789 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Teva Pharmaceutical Industries were worth $8,965,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Aperio Group LLC boosted its position in Teva Pharmaceutical Industries by 25.4% during the second quarter. Aperio Group LLC now owns 366,220 shares of the company’s stock worth $8,906,000 after purchasing an additional 74,131 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Teva Pharmaceutical Industries by 25.5% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 83,473 shares of the company’s stock worth $2,030,000 after purchasing an additional 16,946 shares during the period. TD Asset Management Inc. boosted its position in Teva Pharmaceutical Industries by 10.3% during the second quarter. TD Asset Management Inc. now owns 270,280 shares of the company’s stock worth $6,573,000 after purchasing an additional 25,200 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter worth $995,000. Finally, Virginia Retirement Systems ET AL bought a new position in Teva Pharmaceutical Industries during the second quarter worth $1,267,000. 61.66% of the stock is currently owned by institutional investors.
A number of research firms have commented on TEVA. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, December 3rd. Royal Bank of Canada set a $22.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, November 2nd. Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, November 1st. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 17th. Finally, Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “underperform” rating in a research report on Friday, November 2nd. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $21.94.
In related news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now owns 2,376 shares of the company’s stock, valued at $56,334.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now directly owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. Insiders have sold 7,464 shares of company stock valued at $173,051 in the last three months. Insiders own 0.43% of the company’s stock.
TEVA opened at $19.41 on Friday. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $15.15 and a fifty-two week high of $25.96. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. The firm has a market cap of $20.90 billion, a PE ratio of 4.94, a PEG ratio of 6.20 and a beta of 0.74.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.54 billion. During the same quarter last year, the firm earned $1.00 earnings per share. The company’s revenue was down 19.4% on a year-over-year basis. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Shares Sold by Great West Life Assurance Co. Can” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/12/08/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-great-west-life-assurance-co-can.html.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Leveraged Buyout (LBO)
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.